Seagen (SGEN) Stock Price, News & Analysis

Company Overview

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Key Stats

• Today's Range: $228.74 to $228.74
• 50-Day Range: $228.74 to $228.74
• 52-Week Range: $123.77 to $228.96
• Volume: N/A
• Average Volume: 1.48 million shs
• Market Capitalization: $42.93 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SGEN
• CIK: 1060736
• Web: www.seattlegenetics.com
• Phone: (425) 527-4000
• Fax: 425-527-4001
• Employees: 3,256
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): ($4.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$610.31 million
• Net Margins: -32.61%
• Pretax Margin: -32.12%
• Return on Equity: -28.06%
• Return on Assets: -20.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.67
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: $2.30 billion
• Price / Sales: 18.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.10 per share
• Price / Book: 15.15

Miscellaneous

• Outstanding Shares: 187,698,000
• Free Float: 139,084,000
• Market Cap: $42.93 billion
• Optionable: Optionable
• Beta: 0.32